Allworth Financial LP Acquires 5,534 Shares of Medpace Holdings, Inc. $MEDP

Allworth Financial LP lifted its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 9,708.8% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,591 shares of the company’s stock after purchasing an additional 5,534 shares during the period. Allworth Financial LP’s holdings in Medpace were worth $1,755,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in MEDP. Alps Advisors Inc. boosted its holdings in Medpace by 10.0% during the first quarter. Alps Advisors Inc. now owns 1,098 shares of the company’s stock worth $335,000 after buying an additional 100 shares during the last quarter. Signaturefd LLC increased its stake in shares of Medpace by 10.8% in the 1st quarter. Signaturefd LLC now owns 655 shares of the company’s stock valued at $200,000 after acquiring an additional 64 shares during the last quarter. Dakota Wealth Management raised its position in shares of Medpace by 188.9% in the 1st quarter. Dakota Wealth Management now owns 2,115 shares of the company’s stock valued at $644,000 after acquiring an additional 1,383 shares during the period. Whittier Trust Co. boosted its stake in Medpace by 47.3% during the 1st quarter. Whittier Trust Co. now owns 109 shares of the company’s stock worth $33,000 after acquiring an additional 35 shares during the last quarter. Finally, Victory Capital Management Inc. grew its holdings in Medpace by 41.7% during the first quarter. Victory Capital Management Inc. now owns 23,979 shares of the company’s stock valued at $7,306,000 after purchasing an additional 7,051 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Trading Down 1.1%

Shares of NASDAQ MEDP opened at $591.32 on Friday. The company has a fifty day moving average price of $537.32 and a 200 day moving average price of $420.81. The firm has a market cap of $16.66 billion, a PE ratio of 41.35, a PEG ratio of 2.67 and a beta of 1.42. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $625.00.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. The company had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The company’s quarterly revenue was up 23.7% compared to the same quarter last year. During the same period in the previous year, the company posted $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Transactions at Medpace

In other Medpace news, General Counsel Stephen P. Ewald sold 15,230 shares of the company’s stock in a transaction that occurred on Monday, October 27th. The stock was sold at an average price of $598.85, for a total transaction of $9,120,485.50. Following the completion of the transaction, the general counsel owned 13,343 shares of the company’s stock, valued at $7,990,455.55. This represents a 53.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO August J. Troendle sold 36,196 shares of the firm’s stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $475.90, for a total transaction of $17,225,676.40. Following the transaction, the chief executive officer directly owned 925,799 shares of the company’s stock, valued at $440,587,744.10. This represents a 3.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 134,211 shares of company stock worth $74,459,958. Corporate insiders own 20.30% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on MEDP. Cowen reaffirmed a “sell” rating on shares of Medpace in a research note on Friday, October 24th. BMO Capital Markets initiated coverage on shares of Medpace in a report on Thursday. They issued a “market perform” rating and a $600.00 price target for the company. Truist Financial set a $555.00 price objective on shares of Medpace in a research report on Monday, October 27th. Barclays lifted their target price on Medpace from $425.00 to $485.00 and gave the stock an “underweight” rating in a report on Friday, October 24th. Finally, William Blair reissued a “market perform” rating on shares of Medpace in a research note on Wednesday, July 23rd. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have issued a Hold rating and four have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $487.18.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.